Literature DB >> 10947299

ACE inhibitors after myocardial infarction. Clinical and economic considerations.

A P Davie1.   

Abstract

Economic analysis has been extensively used to guide the use of ACE inhibitors in chronic heart failure. More recently, it has been used to guide the use of ACE inhibitors after myocardial infarction. The results of major clinical trials leave us in no doubt that ACE inhibitors are useful in the treatment of patients after myocardial infarction. The results of economic analysis unanimously indicate that ACE inhibitors are cost effective when used to treat patients after myocardial infarction. Any comparison of the different treatment strategies available suggests that all are comparably cost effective and argues for the widest possible use of ACE inhibitors in this setting. The evidence suggests that, in this context as in so many others, ACE inhibitors remain under-utilized.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947299     DOI: 10.2165/00019053-200017030-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  30 in total

1.  An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom.

Authors:  S Hummel; J Piercy; R Wright; A Davie; A Bagust; J McMurray
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

2.  Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction.

Authors:  J J McMurray; A McGuire; A P Davie; D Hughes
Journal:  Eur Heart J       Date:  1997-09       Impact factor: 29.983

Review 3.  The pharmacoeconomics of ACE inhibitors in chronic heart failure.

Authors:  J McMurray; A Davie
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

4.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

5.  Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.

Authors:  N Sharpe; J Murphy; H Smith; S Hannan
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

6.  The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.

Authors:  C LePen; H Lilliu; T Keller; S Fiessinger
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

7.  Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.

Authors:  L Erhardt; S Ball; F Andersson; P Bergentoft; C Martinez
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

8.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.

Authors:  E Ambrosioni; C Borghi; B Magnani
Journal:  N Engl J Med       Date:  1995-01-12       Impact factor: 91.245

9.  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

10.  Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands.

Authors:  B C Michel; M J Al; W J Remme; J H Kingma; J A Kragten; R van Nieuwenhuizen; B A van Hout
Journal:  Eur Heart J       Date:  1996-05       Impact factor: 29.983

View more
  1 in total

1.  Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4.

Authors:  Claudio Borghi; Ettore Ambrosioni; Stefano Omboni; Arrigo Fg Cicero; Stefano Bacchelli; Daniela Degli Esposti; Salvatore Novo; Dragos Vinereanu; Giuseppe Ambrosio; Giorgio Reggiardo; Dario Zava
Journal:  Clinicoecon Outcomes Res       Date:  2013-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.